Researchers have discovered that disruptions in the brain’s salience network, often tied to tau protein buildup, correlate strongly with behavioral changes in people with early-stage dementia.

An international team of researchers has made a significant breakthrough in Alzheimer's drug development with the ...

The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...

DEPTAC. Based on PROTACs, or protein-targeting chimeras, D20, a dephosphorylation-targeting chimera, delivers PP1 to tau. The C-terminal tail (gray) helps the construct enter cells. [Courtesy of Xiao ...

Further research could also help explain and even predict variation in the onset of behavioral changes in people with ...

AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.

AG03, developed by researchers at the University of Southampton, targets two critical regions of the tau protein linked to ...

An international team of researchers led by Lancaster University has made a promising breakthrough in the development of ...

Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in ...

Researchers from the University of Michigan reveal new insights into early-stage dementia, identifying tau protein as a ...

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized ...